is one of the primary tools used in pharmacovigilance.
We examined the incidence of SJS/TEN in the FAERS database from January 2004 to March 2013. To extract case reports of SJS/ TEN from the FAERS database, SJS/TEN were coded according to the terminology preferred by the Medical Dictionary for Regulatory Activities 16.0. We used the following three preferred terms to match SJS and TEN: SJS/PT10042033, oculomucocutaneous syndrome/PT10030081, and TEN/PT10044223. To detect SJS/TEN incidences, we calculated the reporting odds ratio (ROR), which is established for pharmacovigilance by using a disproportionality analysis. 8 The ROR is an applicable technique that allows for adjustment through logistic regression analysis and offers the advantageous possibility of controlling for covariates. 9 We refined the results with a dedicated correction to detect possible confounders present in the database. The reports were stratified by age as follows: 17 years, 18e39 years, 40e59 years, 60e79 years, and 80 years. The RORs were adjusted for gender, reporting year, and stratified age group. The following logistic model was used:
where Y ¼ reporting year, G ¼ gender, and A ¼ stratified age group. The FAERS contains 4,746,890 reports. After excluding duplicates according to the FDA recommendation and extracting the reports completed with gender and age information, 2,257,902 reports were finally analyzed. The number of reports obtained for each preferred term was 9078 for SJS, 192 for oculomucocutaneous syndrome, and 4076 for TEN. Table 1 summarizes the scores and the reporting ratios. The breakdown of the number of case reports on valdecoxib, lamotrigine, phenytoin, acetaminophen, and furosemide was 1446 (11.0%), 1341 (3.6%), 1076 (6.1%), 834 (0.6%), and 739 (0.8%), respectively. The age-groups of patients with SJS/TEN ranged from infants to the elderly. The number of reported cases was high in the 40-to 79-year-old group. The RORs for the 17-year-old group indicated the highest values for both genders. We further examined the data with the adjusted RORs ( Table 2 ). The effect of the term 17 years was statistically significant in the likelihood ratio test (P < 0.0001). The adjusted ROR of the 17-year-old patients in the whole data extracted from the FAERS database was 2.87 (2.67e3.07) at a 95% confidence interval (CI). The adjusted RORs (95% CI) of valdecoxib, lamotrigine, phenytoin, acetaminophen, and furosemide were 2.54 (0.40e8.98), 2.90 (2.44e3.45), 2.28 (1.79e2.88), 6.15 (4.95e7.62), and 1.58 (0.96e2.46), respectively.
To the best of our knowledge, systematic studies of SJS/TEN that are stratified by age group are very rare. In this study, we demonstrated a relatively high value for the adjusted ROR in patients aged 17 years. We do not have a conclusive explanation for these data. Reports of SJS due to viral infections in young patients who also received acetaminophen might be included in the data. Therefore, acetaminophen may be a causal drug and may explain the high incidence of SJS/TEN in young patients. The pharmacological actions of valdecoxib, lamotrigine, phenytoin, and furosemide are different from that of acetaminophen. Valdecoxib, lamotrigine, phenytoin, and furosemide showed high values for the adjusted RORs in the 17-year-old group. The numbers of reports on valdecoxib, lamotrigine, and phenytoin were higher than the number of reports on acetaminophen. We considered that mycoplasma infection could partially explain the high value of the adjusted RORs of SJS/TEN in the 17-year-old patients.
Another plausible reason for this might be differences in sensitivity to medication between patients aged 17 years and elderly patients. SJS/TEN are also believed to be partially immunemediated, since treating patients with the same drug repeatedly can be associated with the rapid recurrence of SJS/TEN. 10 On the other hand, the genetic background related to the human leukocyte antigen might have an influence on the incidence of SJS/ TEN. 7 Genetic factors that are associated with drug hypersensitivity are a complex issue. In evaluations of the true risk of medications, regional differences in drug prescriptions should be taken into account. The impact of human leukocyte antigen genotyping should
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Allergology International j o u r n a l h o m e p a g e : h t t p : / / w w w . e l se v i e r . c o m / l o c a t e / a l i t be evaluated with respect to a variety of ethnic backgrounds by using well-organized epidemiologic studies, the FAERS database, or both. The FAERS database is subject to many biases such as underreporting, over-reporting, and confounding by comorbidities. 8 In general, the crude ROR is inapplicable to inferences of comparative strengths of causality and only offers a rough indication of the signal strength. 8 The FAERS database is a spontaneous reporting database system and detailed patient information is not included. Therefore, the definition of SJS/TEN in the FAERS database is not stringent. We must highlight this profound limitation in the FAERS database. Despite such limitations that are inherent to spontaneous reporting, it may be acceptable to compare the adjusted RORs of a particular event that are derived from stratified analysis within a particular context. This study was the first to evaluate the relationship between SJS/ TEN and aging by using the FAERS database. We hope that these data will update the information available to clinicians and be potentially useful for improving the management of SJS/TEN.
